SoftOx Solutions AS Logo

SoftOx Solutions AS

Develops non-toxic, AMR-safe antimicrobials for wound care, disinfection & airway infections.

SOFTX | OL

Overview

Corporate Details

ISIN(s):
NO0010811961 (+2 more)
LEI:
549300AETMWJS91G4A50
Country:
Norway
Address:
Martin Linges vei 25, 1364 Fornebu
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

SoftOx Solutions AS is a clinical-stage pharmaceutical company developing a patented, non-toxic antimicrobial technology to address significant global health threats. The company's platform stabilizes a naturally occurring molecule (hypochlorous acid) to create highly effective solutions against a broad spectrum of pathogens, including bacteria, viruses, fungi, and biofilms. A key advantage of this technology is its mechanism of action, which does not contribute to the development of antimicrobial resistance (AMR). The company's primary focus includes an inhalation solution for airway infections, as well as products for advanced wound care and disinfection. SoftOx develops its technology in collaboration with leading scientific and clinical research institutions.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-07 21:17
Regulatory News Service
SoftOx Solutions AS: Private Placement resolved
Norwegian 3.0 KB
2025-10-03 15:23
Share Issue/Capital Change
SoftOx Solutions AS: New Share Capital
English 1.5 KB
2025-10-01 14:35
Legal Proceedings Report
SoftOx Solutions AS: Clinical Trial Application for Dose Escalation / Cystic Fi…
English 2.6 KB
2025-09-25 17:51
Share Issue/Capital Change
SoftOx Solutions AS: Clarification on Placement Commission
English 1.5 KB
2025-09-25 15:08
Share Issue/Capital Change
SoftOx Solutions AS: Private Placements resolved
English 2.0 KB
2025-09-23 09:07
Regulatory News Service
SoftOx Solutions AS: SoftOx builds momentum: CF trial strategy reinforced by HO…
English 3.6 MB
2025-09-23 09:07
Regulatory News Service
SoftOx Solutions AS: SoftOx builds momentum: CF trial strategy reinforced by HO…
English 3.0 KB
2025-09-23 08:00
Regulatory News Service
SoftOx Solutions AS: SoftOx builds momentum: CF trial strategy reinforced by HO…
English 3.6 MB
2025-09-23 08:00
Regulatory News Service
SoftOx Solutions AS: SoftOx builds momentum: CF trial strategy reinforced by HO…
English 2.4 KB
2025-09-17 08:00
Interim Report
SoftOx Solutions AS: Second Quarter/Half-Year Report 2025 - Attachment: SoftOx …
English 1.1 MB
2025-09-17 08:00
Report Publication Announcement
SoftOx Solutions AS: Second Quarter/Half-Year Report 2025
English 367 bytes
2025-09-11 15:59
Capital/Financing Update
SoftOx Solutions AS: Softox Solutions AS exercises on the financing facility wi…
English 1.9 KB
2025-09-08 12:07
Investor Presentation
SoftOx Solutions AS: Presentation Deck and link to today's Investor Update - At…
English 3.7 MB
2025-09-08 12:07
Investor Presentation
SoftOx Solutions AS: Presentation Deck and link to today's Investor Update
English 619 bytes
2025-09-08 08:00
Regulatory News Service
SoftOx Solutions AS: Reminder - Investor Update in connection with the Refinem…
English 1.6 MB

Automate Your Workflow. Get a real-time feed of all SoftOx Solutions AS filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for SoftOx Solutions AS via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden 2CUREX
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden ABERA
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX
ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France ABNX
Abliva Logo
Develops clinical-stage medicines for rare primary mitochondrial diseases to restore cell function.
Sweden ABLI
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France AB
Access Bio, Inc. Logo
Develops and manufactures rapid diagnostic tests for infectious diseases for global health.
United States of America 950130
Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden ACTI

Talk to a Data Expert

Have a question? We'll get back to you promptly.